The global biopharma industry is facing intensifying scrutiny over drug pricing as governments and payers push back against rising healthcare costs. In Canadian Health systems, where public funding pl...
The global biopharma industry is facing intensifying scrutiny over drug pricing as governments and payers push back against rising healthcare costs. In Canadian Health systems, where public funding pl...